The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety profiles of the individual agents. Endometrial cancer originates in the ...